IRVING, Texas; May 29, 2009 – Caris Diagnostics (Caris Dx) – a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology, announced that it has strengthened its hematopathology and oncology franchise with the addition of four experts. Led by Raul C. Braylan, M.D., one of the country’s most respected and prominent hematopathologists as Medical Director of Hematopathology Services, the expanded team provides expert knowledge of molecular technology, diagnostics and flow cytometry for blood and bone marrow cancers.
Read More >>

IRVING, Texas and PHOENIX, Arizona; May 28, 2009 – Caris Diagnostics (Caris Dx), a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology, announced today that it has expanded its Target GI Colon (SM) tumor testing panel for colorectal cancer (CRC) patients to include BRAF mutation analysis. With the expansion, Target GI Colon (SM) is now one of the most comprehensive colorectal testing panels available, leading to better, more effective therapeutic choices for colon cancer patients.
Read More >>

IRVING, Texas, PHOENIX, AZ May 27, 2009: Caris Diagnostics (Caris Dx) – a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology – today announced the appointment of a nationally-renowned oncologist, David Loesch, MD, as Director of Oncology, Clinical Trials and Services.
Read More >>

IRVING, Texas and PHOENIX, Arizona April 20, 2009 – Clinical study results released today at the 100^th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, CO, indicated that the molecular profiling of patients through the Caris Diagnostics’ (Caris Dx)  Target Now™ molecular profiling analysis identifies individual genetic profiles that often drive more informed and effective personalized treatment options.  The findings provide early validation for the application of therapy selection through molecular profiling, resulting in improved patient care and enhanced outcomes.

Read More >>

IRVING, Texas and PHOENIX, Arizona; August 11, 2008 - Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced today the offering of Target GI to physicians nationwide.  Target GI is designed to provide information on the expression of key molecular targets present in colon cancer, providing physicians the most up-to-date information to help in the management of their patients. Read More >>

IRVING, Texas; August 1, 2008 - CDX Holdings, a newly-formed holding company that is the parent company of Caris Diagnostics (Caris Dx) and Caris Molecular Diagnostics (CMDx), announced today that George Poste, D.V.M., Ph.D, F.R.C. Path, F.R.S., will be expanding his involvement with the company, serving as Non-Executive Vice Chairman and Chief Scientific Advisor of CDX Holdings and Non-Executive Chairman of CMDx.  Dr. Poste has been a Director of Caris Dx, and now CDX Holdings, since November of 2006. He also acts as Senior Technical Advisor to Caris, Ltd., which owns a controlling stake in CDX Holdings. Read More >>

IRVING, Texas and PHOENIX, Arizona; June 24, 2008: Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix) developed by Amgen. Read More >>

Clinical trial data and cutting-edge testing give key insights in the fight against basal cell carcinoma and pancreatic cancer.

San Diego , CA / Phoenix, AZ - April 15, 2008: Clinical researchers at Scottsdale Healthcare and TGen today announced the results of two clinical trials that show promise for patients battling cancer.

The Phase I clinical trial findings, presented at the this weeks Annual Meeting of the American Association for Cancer Research by Daniel Von Hoff, MD, FACG, focused on basal cell carcinoma (BCC) and pancreatic cancer. The Arizona trials were conducted at TGen’s Clinical Research Service (TCRS) at Scottsdale Healthcare, a strategic alliance between TGen and Scottsdale Healthcare’s Clinical Research Institute. Read More >>

Minneapolis, MN / Irving, TX - February 06, 2008: Nearly nine in ten (88%) gastroenterologists either currently capture Quality Indicator (QI) data or plan to do so in the next two years, according to a January 2008 independent, national survey of gastroenterologists commissioned by ProVation® Medical and Caris Diagnostics. Of those surveyed who collect QI data, majorities cited colonoscopic withdrawal time (62%) and rate of adenomatous polyp detection (52%) as indicators they capture most frequently. Read More >>

Irving, Texas - January 15, 2008: Caris Diagnostics, a leading provider of diagnostic services in anatomic pathology and molecular testing, today announced the hiring of another nationally-renowned dermatopathologist for its Phoenix laboratory. Iftikhar “Ifty” Ahmed, M.D. has joined Caris Diagnostics to support the growing dermatopathology practice for the company. Read More >>